EUVIMEDEUVIMED entdecken
Crossref

Medium‐Chain Fatty Acids Ameliorate Liver Fibrosis by Phosphorylating Hepatic Stellate Cell Forkhead Box Protein O1

Masashi Sakaki iD, Joo-Ri Kim-Kaneyama, Masahito Noguchi iD, Aya Miyauchi, Xiao-Feng Lei, Momoko Kobayashi-Tanabe, Mayumi Homma, Toshiko Yamochi, Akira Miyazaki, Hitoshi Yoshida

Liver International · 2025

DOI: 10.1111/liv.70270 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, 2025. Verfasst von Masashi Sakaki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine, Showa Medical University, Tokyo, Japan. Hauptthemen laut MEDLINE: Hepatic Stellate Cells, Forkhead Box Protein O1, Liver Cirrhosis, Fatty Acids. Die Arbeit nennt 43 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Liver fibrosis is a common adverse prognostic factor in various liver conditions. Medium‐chain fatty acids (MCFAs), unique fatty acids transported directly to the liver, undergo rapid metabolism, providing energy to hepatocytes and acting as signalling molecules that mediate diverse cellular functions. Nonetheless, the precise impact of MCFAs on the pathogenesis of liver fibrosis remains incompletely understood. This study aimed to investigate the anti‐fibrotic role of MCFAs and their therapeutic potential for liver fibrosis.

Methods

To investigate the effects of MCFAs on liver fibrosis and pathophysiology, we conducted experiments utilising a male mouse model of metabolic dysfunction‐associated steatohepatitis (MASH). The anti‐fibrotic effect of MCFAs was evaluated using human hepatic stellate cells (hHSCs). We analysed the role of forkhead box protein O1 (FOXO1), a transcription factor closely involved in metabolic regulation, in MCFA‐stimulated HSCs.

Results

MCFA feeding significantly improved liver fibrosis and lipid accumulation in mice. Additionally, C10 inhibited collagen production, migration, and proliferation of activated hHSCs. FOXO1 inhibitors suppressed collagen production by hHSCs, and C10 stimulation induced FOXO1 Ser256 phosphorylation. Mechanistically, C10 induced phosphorylation of FOXO1 via AKT phosphorylation in a PI3K‐independent manner. Notably, elevated levels of phosphorylated FOXO1 were observed in hepatic tissue from MASH model mice treated with an MCFA‐rich diet, accompanied by its translocation from the nucleus to the cytoplasm.

Conclusions

MCFAs, particularly C10, may modulate hHSC transcriptional inactivation through phosphorylation of the Akt–FOXO1 pathway. This mechanism of regulating the hHSC function via C10 might represent a novel therapeutic approach for liver fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatic Stellate CellsForkhead Box Protein O1Liver CirrhosisFatty AcidsAnimalsMaleHumansMicePhosphorylationDisease Models, AnimalMice, Inbred C57BLSignal TransductionCell ProliferationLiverCell MovementCollagenProto-Oncogene Proteins c-akt

Stichwörter der Autor:innen

anti‐fibrosiscapric acidmedium chain triglyceridemetabolic dysfunction associated steatohepatitismetabolic dysfunction associated steatotic liver disease

Substanzen

Forkhead Box Protein O1Fatty AcidsFoxo1 protein, mouseCollagenFOXO1 protein, humanProto-Oncogene Proteins c-akt

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Medicine, Showa Medical University, Tokyo, Japan.
  • Institute for Extracellular Matrix Research, Showa Medical University, Tokyo, Japan.
  • Department of Dermatology, Showa Medical University, Tokyo, Japan.
  • Department of Pathology, Showa Medicine University, Tokyo, Japan.

ORCID-Profile: Masashi Sakaki, Masahito Noguchi

Förderung

  • Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development

Zitieren

APA

Sakaki, M., Kim-Kaneyama, J. R., Noguchi, M., Miyauchi, A., Lei, X. F., Kobayashi-Tanabe, M., Homma, M., Yamochi, T., Miyazaki, A., & Yoshida, H. (2025). Medium‐Chain Fatty Acids Ameliorate Liver Fibrosis by Phosphorylating Hepatic Stellate Cell Forkhead Box Protein O1. Liver International. https://doi.org/10.1111/liv.70270

Vancouver

Sakaki M, Kim-Kaneyama JR, Noguchi M, Miyauchi A, Lei XF, Kobayashi-Tanabe M, et al. Medium‐Chain Fatty Acids Ameliorate Liver Fibrosis by Phosphorylating Hepatic Stellate Cell Forkhead Box Protein O1. Liver International. 2025. doi:10.1111/liv.70270

BibTeX
@article{Sakaki2025,
  author = {Sakaki, Masashi and Kim-Kaneyama, Joo-Ri and Noguchi, Masahito and Miyauchi, Aya and Lei, Xiao-Feng and Kobayashi-Tanabe, Momoko and Homma, Mayumi and Yamochi, Toshiko and Miyazaki, Akira and Yoshida, Hitoshi},
  title = {Medium‐Chain Fatty Acids Ameliorate Liver Fibrosis by Phosphorylating Hepatic Stellate Cell Forkhead Box Protein O1},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.70270}
}
Kostenlos starten →